Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents.
If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.
Company Details
- Employees
- 240
- Founded
- -
- Address
- 333 Twin Dolphin Drive, Suite 600, Redwood City,ca 94065,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.coherus.com
- Keywords
- biotechnology and Immuno-oncology.
- HQ
- Redwood City, CA
Coherus Oncology Questions
Coherus Oncology's website is http://www.coherus.com
Coherus Oncology's LinkedIn profile is https://www.linkedin.com/company/coherus-oncology
Coherus Oncology has
240 employees.
View email and phone details for 240
employees at Coherus Oncology.
Coherus Oncology's industry is
Biotechnology Research
Coherus Oncology's top competitors are
Corcept Therapeutics,
Cytokinetics,
Arcutis Biotherapeutics, Inc. (Nasdaq: Arqt),
Jazz Pharmaceuticals,
Agios Pharmaceuticals,
Crinetics Pharmaceuticals,
Bridgebio,
Exelixis,
Ionis Pharmaceuticals, Inc.,
Apellis Pharmaceuticals.
Coherus Oncology's categories are Biotechnology Research
Coherus Oncology's founding year is 2010
